
European Medicines Agency is expected to approve AstraZeneca Plc's (NASDAQ:AZN) antibody-based COVID-19 vaccine for preventing COVID-19 infections, Reuters reported citing two people familiar with the review.
The treatment is meant for adults whose immune system is too weak to respond to vaccines.